

Duravest, Inc.
1040 S. Milwaukee Ave., Suite 250
Wheeling (Chicago), IL 60090, USA
Tel.: +1 847 791 5677
Fax: +1 847 520 3037
Email: info@duravestinc.com



About Us

Duravest, Inc. is a public holding company that strategically acquires and develops next-generation medical technologies with own funds. It is an investment vehicle. Duravest's business model encompasses two value-added components:

Investment vehicle

to facilitate the efficient deployment of internal Duravest-based funds and/or 3rd-party funding.

Business accelerator

to accelerate business and technological development in the challenging area of medical and bio-medical technologies.

Duravest generates value for its shareholders by developing its subsidiaries into appropriate acquisition targets or public offering entities.

Investment Stage: Duravest typically invests in companies in need of funding for its later staged developments and pre-commercialisation phase. Based on our funding capabilities and our extensive network in the industry, Duravest will bring added value to the investments. During the last years, Duravest has invested millions of US Dollars in the United States, Canada and Europe. The business is operated out of the United States and Switzerland. Our investment focus is a truly international one.

Sourcing: We learn about opportunities through two major channels - entrepreneurs and investors. Our extensive relationships with academia and the medical community bring a wide range of potential deals to our attention. In addition, our industry reputation as a thought leader in the area of medical technologies naturally brings a large number of opportunities to our attention. Our Board members are also actively involved in bringing us a wide range of high-quality ideas and opportunities. We also foster strong partnerships with a number of leading investment firms who both bring potential deals (in the areas of medical technologies) and also co-invest in such deals.

Evaluation: We engage a broad range of opinions to help us fully evaluate investments that are brought to us. All proposals are initially evaluated by the core management team on a weekly basis. Our medical and scientific advisors as well as any other outside experts as appropriate evaluate investments that pass our primary round of criteria. In the third round a comprehensive due-diligence program is initiated. It should be noted that many investments come to us through our investment partners and, as such, may already have undergone some level of due diligence. Deals that eventually close can be considered to have undergone among the most rigorous evaluation processes in the field.

Investment Process: Duravest takes a highly structured approach to the sourcing, evaluation and development of its investments. All three of these elements are essential to the ultimate success of an investment. A broad palette of high-quality deals from the outset is critical. A rigorous evaluation process and an engaged development of the acquired company is essential to maximize success. Careful evaluation and due diligence are the cornerstone of any investment process. Our unique strengths in both the sourcing and development of investments are also of great value in optimizing the ROI of our carefully selected investments.

1040 S. Milwaukee Ave., Suite 250 | Wheeling (Chicago), IL 60090 U.S.A. | T 1-847-791-5677 | F 1-847-520-3037 |
info@duravestinc.com

Investing in and Developing Next Generation Medical Technologies